AviadoBio

Executive Summary

AviadoBio is a UK-based biotechnology company founded in 2021, focused on developing gene therapies for neurodegenerative diseases using a proprietary neuroanatomy-led approach and precision delivery technologies. The company's lead program targets frontotemporal dementia (FTD) caused by progranulin (GRN) mutations, with a Phase 1/2 clinical trial (AVB-001) underway. AviadoBio's technology leverages AAV-based vectors to deliver functional genes directly to affected brain regions, aiming for one-time, disease-modifying treatments. The company also has preclinical programs for ALS and other neurodegenerative conditions. As a privately held, early-stage company, AviadoBio's success hinges on positive clinical data, regulatory progress, and strategic partnerships.

Upcoming Catalysts (preview)

• H2 2026Interim Phase 1/2 data for AVB-001 in FTD40% success
• 2026Partnership or licensing deal for AAV delivery platform30% success